CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed
Drug / intervention
niacin +6 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00000539
NCT00000539Phase 3Completed
CompareCT.gov

Arterial Disease Multifactorial Intervention Trial (ADMIT)

National Heart, Lung, and Blood Institute (NHLBI)·interventional·Posted Oct 28, 1999·Updated Jul 12, 2016

In Brief

A Phase 3 clinical trial evaluating niacin, pravastatin, and 5 other interventions for Arterial Occlusive Diseases and 4 related conditions. Completed.

Detailed Summary

To evaluate, in asymptomatic and symptomatic participants with peripheral arterial disease, the feasibility of recruitment and adherence, efficacy and safety of HDL-C raising along with effective control of LDL-C levels, antioxidant therapy, antithrombotic therapy, and their combinations.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsArterial Occlusive Diseases, Cardiovascular Diseases, Heart Diseases, Vascular Diseases, Diabetes Mellitus
Countries--
Collaborators--

Timeline

Phase 3CompletedFinished
199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 28, 1999
Enrollment StartSep 1, 1992
Study CompletionMar 1, 1999
TodayJul 2, 2026
Posted 26.7 years ago

Interventions

niacindrug

pravastatindrug

beta-carotenedrug

vitamin Edrug

dietary supplementsbehavioral

vitamin Cdrug

warfarindrug